Novel Strategies Incorporating Arsenic Trioxide into the Initial Treatment of Acute Promyelocytic Leukemia (APL)
Ades L et al. Arsenic trioxide (ATO) in the consolidation treatment of newly diagnosed APL — First interim analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL Group. Proc ASH 2010; Abstract 505.
Ravandi F et al. Phase II study of all-trans retinoic acid (ATRA), arsenic trioxide (ATO), with or without gemtuzumab ozogamicin (GO) for the frontline therapy of patients with acute promyelocytic leukemia (APL). Proc ASH 2010;Abstract 1080.
Dr Smith is Associate Professor of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland.
|